Breaking Finance News

A statement released earlier today by Stifel Nicolaus about Vertex Pharmaceuticals (NASDAQ:VRTX) bumps down the target price to $105.00

Vertex Pharmaceuticals (NASDAQ:VRTX) had its target price lowered to $105 by Stifel Nicolaus in a report released 8/16/2016. The updated target price implies a possible upside of 0.05% based on the bussiness’ most recent stock close price.

Yesterday Vertex Pharmaceuticals (NASDAQ:VRTX) traded 0.42% lower at $100.26. VRTX’s 50-day average is $98.19 and its two hundred day average is $89.42. The last stock close is up 3.68% from the two hundred day moving average, compared to the S&P 500 which has decreased -0.01% over the same time period. Trading volume was was up over the average, with 2,130,264 shares of VRTX changing hands over the typical 1,298,770 shares..

See Graphic Below:

Vertex Pharmaceuticals (NASDAQ:VRTX)

With a market cap of $0.0, Vertex Pharmaceuticals has a one-year low of $75.90 and a one-year high of $136.97 with a P/E ratio of 0.

A total of 20 brokerages have issued a report on the company. Eight analysts rate the stock a strong buy, 10 analysts rate the stock a buy, seven firms rate the stock a hold, 0 rate the company to underperform, and finally 0 analystsrate the company as sell with a consensus target of $110.30

General Company Details For Vertex Pharmaceuticals (NASDAQ:VRTX)

Vertex Pharmaceuticals Incorporated is engaged in the business of discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company operates in pharmaceuticals segment. Its business is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. Its marketed medicines are ORKAMBI and KALYDECO, which are approved to treat patients with CF having specific mutations in their CF transmembrane conductance regulator (CFTR) gene. It has multiple development programs in the field of CF, including VX-661, VX-371, and VX-152 and VX-440. It is engaged in various other research and mid- and early-stage development programs, such as programs in the areas of oncology, pain and neurology. Its oncology drug candidates include VX-970, VX-803 and VX-984; pain drug candidates include VX-150 and VX-241, and and acute spinal cord injury drug candidate include VX-210.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.